CO2024012457A2 - Formas puras de aticaprant cristalino - Google Patents
Formas puras de aticaprant cristalinoInfo
- Publication number
- CO2024012457A2 CO2024012457A2 CONC2024/0012457A CO2024012457A CO2024012457A2 CO 2024012457 A2 CO2024012457 A2 CO 2024012457A2 CO 2024012457 A CO2024012457 A CO 2024012457A CO 2024012457 A2 CO2024012457 A2 CO 2024012457A2
- Authority
- CO
- Colombia
- Prior art keywords
- aticaprant
- crystalline
- pure forms
- solvates
- pure
- Prior art date
Links
- ZHPMYDSXGRRERG-DEOSSOPVSA-N aticaprant Chemical compound CC1=CC(C)=CC([C@H]2N(CCC2)CC=2C=CC(OC=3C(=CC(=CC=3)C(N)=O)F)=CC=2)=C1 ZHPMYDSXGRRERG-DEOSSOPVSA-N 0.000 title abstract 4
- 229940121408 aticaprant Drugs 0.000 title abstract 4
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 | |
| PCT/IB2023/052082 WO2023170547A1 (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline aticaprant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024012457A2 true CO2024012457A2 (es) | 2024-09-30 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0012457A CO2024012457A2 (es) | 2022-03-07 | 2024-09-13 | Formas puras de aticaprant cristalino |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (https=) |
| EP (1) | EP4489748A1 (https=) |
| JP (1) | JP2025508071A (https=) |
| KR (1) | KR20240158951A (https=) |
| CN (1) | CN119156210A (https=) |
| AU (1) | AU2023231493A1 (https=) |
| CA (1) | CA3254503A1 (https=) |
| CL (1) | CL2024002643A1 (https=) |
| CO (1) | CO2024012457A2 (https=) |
| IL (1) | IL315411A (https=) |
| JO (1) | JOP20240195A1 (https=) |
| MX (1) | MX2024010978A (https=) |
| PE (1) | PE20242109A1 (https=) |
| TW (1) | TW202345795A (https=) |
| WO (1) | WO2023170547A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) * | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| PH12023552963A1 (en) * | 2021-05-04 | 2024-03-11 | Janssen Pharmaceuticals Inc | Compositions and methods for the treatment of depression |
-
2023
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240158951A (ko) | 2024-11-05 |
| EP4489748A1 (en) | 2025-01-15 |
| JOP20240195A1 (ar) | 2024-09-05 |
| JP2025508071A (ja) | 2025-03-21 |
| CL2024002643A1 (es) | 2025-01-24 |
| AU2023231493A1 (en) | 2024-10-24 |
| TW202345795A (zh) | 2023-12-01 |
| US20250326714A1 (en) | 2025-10-23 |
| WO2023170547A1 (en) | 2023-09-14 |
| MX2024010978A (es) | 2024-12-06 |
| CN119156210A (zh) | 2024-12-17 |
| PE20242109A1 (es) | 2024-10-28 |
| IL315411A (en) | 2024-11-01 |
| CA3254503A1 (en) | 2023-09-14 |
| US20230348377A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024012457A2 (es) | Formas puras de aticaprant cristalino | |
| CO2023008362A2 (es) | Degradadores de irak y sus usos | |
| MX2021006154A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
| CO2023006818A2 (es) | Degradadores de irak y sus usos | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| CO2022012594A2 (es) | Inhibidores del eif4e y sus usos | |
| CO2024004970A2 (es) | Agentes degradantes de tyk2 y sus usos | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| CL2024003587A1 (es) | Inhibidores de mek y usos de estos | |
| MX2020009147A (es) | Moduladores de la expresion de irf4. | |
| MX2019009759A (es) | Composiciones de peptido estables. | |
| MX2025006853A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos | |
| CO2021014747A2 (es) | Métodos para el tratamiento de βeta-talasemia | |
| MX2022014254A (es) | Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| MX2023008634A (es) | Análogos de rapamicina y usos de estos. | |
| CL2024002103A1 (es) | Métodos para tratar amiloidosis al | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| CL2023003033A1 (es) | Composiciones y métodos para el tratamiento de la miastenia gravis pediátrica. |